Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and Eli Lilly NYSE:LLY (Zepbound) Today I read this: WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US

Are Dietary Drug Stocks Eli Lilly and Novo Nordisk Ready To Rise Again?

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Is Novo Nordisk Stock a Buy Right Now?

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest starter dose.

Novo Nordisk Launches Wegovy Weight-Loss Drug in China

Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available from private employers and insurers, according to an analysis shared with Reuters.

Medicaid dominates coverage of Novo, Lilly weight-loss drugs

Novo Nordisk (NYSE:NVO) has begun rolling out its Wegovy weight loss drug in China at well below the price of the product in the US. A month's supply of the starter dose of Wegovy in China has been priced at 1,400 yuan ($193.27), according to Chinese financial media outlet Yicai.

Novo Nordisk launches Wegovy weight drug in China at fraction of price

Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Novo Nordisk A/S - share repurchase programme

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market.

Novo Nordisk has launched obesity drug Wegovy in China

Vertex Pharmaceuticals

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it's unclear whether they can ramp up production enough.

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready To Meet Demand?

Moderna

Pfizer

SPDR S&P Biotech ETF

With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers.

Trump Taps RFK for HHS: Time to Avoid Biotech?

AstraZeneca

BioNTech SE

Novavax

In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.

Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head

Amgen

Terns Pharmaceuticals

Viking Therapeutics

Zealand Pharma

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Novo Nordisk says it is gradually phasing out human insulin pens globally

Catalent

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said.

EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Novo Nordisk (NVO) is a Strong Growth Stock

Novo drug CagriSema, which combines semaglutide with cagrilintide, could help patients lose 25% of their body weight.

Novo Stock Has Been Slammed. How a New Weight-Loss Drug Could Boost Shares by 10%.

When it comes to weight loss drugs, Ozempic has become a phenomenon.

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong, with no signs of business deterioration. Despite Eli Lilly's underperformance in GLP-1 sales, Novo Nordisk's diabetes and obesity treatments, especially Ozempic and Wegovy, continue to show robust growth. Legal concerns over compounded versions of Ozempic and Wegovy exist, but I believe Novo Nordisk's brand trust and regulatory backing will mitigate long-term impact.

Novo Nordisk: Be Greedy When Others Are Fearful

The good times aren't over, but the peak of the party might be passing.

Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?

Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 750.42 per share and has been calculated as the three-day volume weighted average market price from 6 November 2024 to 8 November 2024 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme

Bristol-Myers

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Ensign Group

Royal Caribbean Cruises

According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S.

These 3 Stocks Are Winning Thanks to Baby Boomers

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as underwhelming guidance for next year overshadowed strong sales growth for its popular Wegovy weight-loss drug.

Novo shares hits 9-month low as 2025 guidance underwhelms

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said.

News for Novo Nordisk Stock (NVO)